Glucocorticoid Receptor 

 192 Products   192 Products   1696 Diseases   102622 News 


«12...6869707172737475767778...11901191»
  • ||||||||||  azathioprine / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  MOGwAI: Azathioprine in MOGAD (clinicaltrials.gov) -  Feb 4, 2025   
    P3,  N=126, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Jan 2029 --> Dec 2029 | Trial primary completion date: Jan 2026 --> Dec 2026
  • ||||||||||  Cortone (cortisone acetate) / Merck (MSD)
    Preclinical, Journal:  A mouse model of immunosuppression facilitates oral Candida albicans biofilms, bacterial dysbiosis and dissemination of infection. (Pubmed Central) -  Feb 4, 2025   
    Here, we used a mouse model of oropharyngeal candidiasis (OPC) with cortisone acetate injection on alternate days and a continuous supply of C. albicans in drinking water for three days, resulting in immunosuppression...Targeted 16S rRNA and ITS2 amplicon sequencing of microbes from the fecal samples of mice confirmed the above results in the stool samples and revealed an inverse correlation of beneficial microbes in the dysbiosis condition. Our study shows that mucosal-oral infection of C. albicans under immunosuppressed conditions causes tissue damage and invasion in local and distant organs; the invasion may be aided by the overgrowth of the resident endogenous Enterobacteriaceae and other members, including the opportunistic pathogen Enterococcus faecalis.
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Journal:  Balloon eustachian tuboplasty in chronic suppurative otitis media and dilatory eustachian tube dysfunction: a randomized controlled trial. (Pubmed Central) -  Feb 4, 2025   
    In this prospective, multicenter, randomized controlled trial, a total of 116 participants (121 ears) treated between January 2021 and June 2023 were randomly assigned (1:1) to receive either BET with MM or MM alone (fluticasone furoate nasal steroid spray)...No serious procedure-related or device-related adverse events occurred in either group during the 8-week follow-up. Our trial suggests that BET, combined with MM, demonstrated superiority over MM alone, along with its safety, in treating dilatory ET dysfunction in patients with COM.
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Trial completion date:  CONTRAC: Cemiplimab in AlloSCT/SOT Recipients With CSCC (clinicaltrials.gov) -  Feb 4, 2025   
    P1/2,  N=12, Active, not recruiting, 
    Our trial suggests that BET, combined with MM, demonstrated superiority over MM alone, along with its safety, in treating dilatory ET dysfunction in patients with COM. Trial completion date: Jan 2025 --> Jan 2026
  • ||||||||||  Review, Journal:  The latest developments in synthetic approaches to duchenne muscular dystrophy. (Pubmed Central) -  Feb 3, 2025   
    Although corticosteroids remain the standard treatment, newly approved drugs such as exon-skipping therapies, vamorolone, delandistrogene moxeparvovec, and givinostat provide new treatment options...The accelerated FDA review process has enabled faster approval of new medications; however many have provided minimal clinical benefit to patients. Despite these challenges, continued drug development and innovative research offer hope to patients.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Journal:  Hypokalemic paralysis in an adolescent following dexamethasone and B12 injection: A case report and literature review. (Pubmed Central) -  Feb 3, 2025   
    Recently, we experienced a case of hypokalemic paralysis in an adolescent following intramuscular injections of dexamethasone and vitamin B12...Meanwhile, clinicians should be cautious when prescribing glucocorticoids, particularly in combination with B12 supplements. This includes ensuring that both are administered only when clinically indicated, monitoring vital signs and serum potassium levels in at-risk patients, and considering alternatives when appropriate.
  • ||||||||||  Journal:  From Pruritus to Bullae: Recognizing Furosemide-Induced Bullous Pemphigoid in an Elderly Male Patient. (Pubmed Central) -  Feb 3, 2025   
    Ultimately, biweekly dupilumab injections effectively controlled the symptoms...Clinicians should maintain a high index of suspicion for BP in elderly patients with unexplained pruritus, especially when standard treatments are ineffective. Additionally, this case highlights the importance of considering drug-induced BP, with furosemide recognized as a potential trigger.
  • ||||||||||  dexamethasone / Generic mfg., Metopirone (metyrapone) / Perrigo Company
    Journal:  Finding the Culprit: Cushing Syndrome Secondary to Lung Carcinoid Tumor. (Pubmed Central) -  Feb 3, 2025   
    The ACTH and cortisol levels remained elevated after a low-dose dexamethasone suppression test...Due to symptoms of severe hypercortisolism including hypokalemia and worsening mood changes, the patient was started on metyrapone as a bridge to surgery...Medical therapy aids in managing severe hypercortisolism in ACTH-secreting tumors until definitive surgical treatment can be undertaken. This case underscores the critical importance of promptly recognizing EAS and the resulting severe hypercortisolism symptoms because early surgical intervention can lead to a cure.
  • ||||||||||  Lysodren (mitotane) / Perrigo Company, hydrocortisone / Generic mfg., Isturisa (osilodrostat) / Novartis, Recordati
    Journal:  A Case of Severe Cushing Syndrome due to Metastatic Adrenocortical Carcinoma Treated With Osilodrostat. (Pubmed Central) -  Feb 3, 2025   
    The patient received chemotherapy and mitotane; however, mitotane was stopped after development of hemolytic anemia...This was managed with hydrocortisone in a block-and-replace dosing strategy...Although osilodrostat is currently only approved for use in pituitary Cushing disease, we found it effective in off-label use to treat Cushing syndrome due to ACC. Using a block-and-replace treatment strategy was a practical intervention after development of adrenal insufficiency.
  • ||||||||||  Journal:  Analgesic Quality Improvement in Paravertebral Blocks for Pediatric Nuss Procedure: An Exploratory Report on the Effects of Perineural Combined Glucocorticoids. (Pubmed Central) -  Feb 3, 2025   
    The primary outcome studied was postoperative opioid consumption measured by oral morphine milligram equivalents (MME)...The experimental group had 72% lower postoperative opioid usage than the standard group during the hospitalization (p < 0.001) with comparable pain scores and hospital length of stay and no increase in wound dehiscence or other complications. The addition of dexamethasone sodium phosphate and methylprednisolone acetate to continuous paravertebral blocks significantly decreased postoperative opioid consumption while maintaining comfort pain scores.
  • ||||||||||  dexamethasone / Generic mfg., gentamicin sulfate / Generic mfg.
    Review, Journal, Video:  Endothermal pupilloplasty : A (Pubmed Central) -  Feb 3, 2025   
    The addition of dexamethasone sodium phosphate and methylprednisolone acetate to continuous paravertebral blocks significantly decreased postoperative opioid consumption while maintaining comfort pain scores. A
  • ||||||||||  Darzalex (daratumumab) / J&J
    Review, Journal:  Survival trends using DPd vs. other triplets in early RRMM patients: a population-adjusted indirect treatment comparison. (Pubmed Central) -  Feb 3, 2025   
    This study conducted population-adjusted indirect comparisons of overall survival (OS) for DPd vs. daratumumab, carfilzomib, and dexamethasone (DKd) and daratumumab, bortezomib, and dexamethasone (DVd)...A consistent OS benefit was observed for DPd vs. DKd and DVd for patients with RRMM, using both STC and MAIC methods. The findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Trial completion date, Trial primary completion date:  Isatuximab As Upfront Therapy for the Treatment of High Risk AL Amyloidosis (clinicaltrials.gov) -  Feb 3, 2025   
    P1,  N=11, Active, not recruiting, 
    The findings of this study support the use of DPd over DKd and DVd for the treatment of patients with early RRMM. Trial completion date: Nov 2024 --> Jul 2026 | Trial primary completion date: Nov 2024 --> Jul 2025
  • ||||||||||  dexamethasone / Generic mfg., progesterone / Generic mfg., metformin / Generic mfg.
    Journal:  Insulin Resistance in an Underweight Woman with Polycystic Ovary Syndrome: A Case Study. (Pubmed Central) -  Feb 3, 2025   
    Significant improvement in menstrual cycle, acne, and hirsutism was observed after 6 months. CONCLUSIONS This report has highlighted that when patients with PCOS also have insulin resistance, they may be of normal weight or underweight and require a multidisciplinary approach to diagnosis and management.